Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT

Minke H T Hartman, Jake K B Prins, Remco A J Schurer, Erik Lipsic, Chris P H Lexis, Anouk N A van der Horst-Schrivers, Dirk J van Veldhuisen, Iwan C C van der Horst, Pim van der Harst

Research output: Contribution to journalArticleAcademicpeer-review


OBJECTIVES: Preclinical and clinical studies suggested cardioprotective effects of metformin treatment. In the GIPS-III trial, 4 months of metformin treatment did not improve left ventricular ejection fraction in patients presenting with ST-elevation myocardial infarction (STEMI). Here, we report the 2-year follow-up results.

METHODS: Between January 2011 and May 2013, 379 STEMI patients without diabetes undergoing primary percutaneous coronary intervention were randomized to a 4-month treatment with metformin (500 mg twice daily) (N = 191) or placebo (N = 188) in the University Medical Center Groningen. Two-year follow-up data was collected to determine its effect on predefined secondary endpoints: the incidence of major adverse cardiac events (MACE), its individual components, all-cause mortality, and new-onset diabetes.

RESULTS: For all 379 patients all-cause mortality data were available. For seven patients (2%) follow-up data on MACE was limited, ranging from 129 to 577 days. All others completed the 2-year follow-up visit. Incidence of MACE was 11 (5.8%) in metformin and 6 (3.2%) in placebo treated patients [hazard ratio (HR) 1.84, confidence interval (CI) 0.68-4.97, P = 0.22]. Three patients died in the metformin group and one in the placebo treatment group. Individual components of MACE were also comparable between both groups. New-onset diabetes mellitus was 34 (17.8%) in metformin and 32 (17.0%) in placebo treated patients (odds ratio 1.15, CI 0.66-1.98, P = 0.84). After multivariable adjustment the incidence of MACE was comparable between the treatment groups (HR 1.02, CI 0.10-10.78, P = 0.99).

CONCLUSIONS: Four months metformin treatment initiated at the time of hospitalization in STEMI patients without diabetes did not exert beneficial long-term effects.

TRIAL REGISTRATION: Identifier: NCT01217307.

Original languageEnglish
Pages (from-to)939-946
Number of pages8
JournalClinical Research in Cardiology
Issue number12
Publication statusPublished - 1 Dec 2017
Externally publishedYes


  • Administration, Ophthalmic
  • Aged
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents/administration & dosage
  • Magnetic Resonance Imaging, Cine
  • Male
  • Metformin/administration & dosage
  • Middle Aged
  • Percutaneous Coronary Intervention
  • Prospective Studies
  • ST Elevation Myocardial Infarction/diagnosis
  • Time Factors
  • Treatment Outcome
  • Heart failure
  • Percutaneous coronary intervention
  • Diabetes
  • Metformin
  • Acute myocardial infarction


Dive into the research topics of 'Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT'. Together they form a unique fingerprint.

Cite this